주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
Annual Meeting of The Endocrine Society (ENDO 2025)
12 July - 15 July, 2025, United States
Navepegritide tied to increased growth velocity in children with ACH
2025-10-01
Once-weekly treatment with
navepegritide was associated with significantly improved annualized growth velocity (AGV) in children with achondroplasia (ACH) compared with placebo, according to results from the pivotal ApproaCH trial presented at ENDO 2025.
Age at menarche may signal health risks
2025-10-01
Findings from The Brazilian Longitudinal Study of Adult Health (ELSA-Brazil) presented at ENDO 2025 demonstrate an association between early and late age at menarche and distinct cardiometabolic and reproductive health risks.
Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women
2025-10-01
In postmenopausal women with overweight or
obesity
, the use of tirzepatide alongside
menopause hormone therapy
appears to yield better weight loss outcomes than treating with tirzepatide alone, findings from a real-world analysis have shown.
GLP-1 drugs can raise testosterone levels in men
2025-10-01
The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.
Intermittent energy restriction stands out for improving outcomes in people with T2D, obesity
2025-10-01
In individuals with type 2 diabetes (T2D) and obesity, an intermittent energy restriction (IER) diet helps with glucose control, with the advantage of improving insulin sensitivity, reducing triglycerides, and being easier to follow compared with other dietary interventions, as shown in a single-centre randomized controlled trial.
Setmelanotide lowers BMI in patients with acquired hypothalamic obesity
2025-10-01
Treatment with setmelanotide results in significant BMI reductions in individuals with acquired hypothalamic
obesity
compared with placebo, with an acceptable safety profile, as shown by the results of a phase III study presented at ENDO 2025.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
